Publications

Selected Publications
                     Whittle, S.B., V. Smith, E. Doherty, S. Zhao, S. McCarty, and P.E. Zage.  2017.  Overview and Recent Advances in the Treatment of Neuroblastoma.  Expert Reviews of Anticancer Therapy.  17(4): 369-86.  PMID:  28142287.

                     Zage, P.E., S.B. Whittle, J.M. Shohet.  2017.  CD114:  A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.  Journal of Cellular Biochemistry.  118(2):  221-31.  PMID:  27428599

                     Whittle, S.B., K. Patel, L. Zhang, S.E. Woodfield, M. Du, V. Smith, P.E. Zage.  2016.  The Novel Kinase Inhibitor Ponatinib Is An Effective Antiangiogenic Agent Against Neuroblastoma.  Investigational New Drugs.  34(6): 685-92.  PMID:  27586230.

                     Du, M., L. Zhang, K.A. Scorsone, S.E. Woodfield, P.E. Zage.  2016.  Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.  Scientific Reports. 6, 27458.  PMID:  27282514.

                     Woodfield, S.E., R. Guo, Y. Liu, A.M. Major, E.F. Hollingsworth, S.M. Indiviglio, S.B. Whittle, Q. Mo, A.J. Bean, M. Ittmann, D. Lopez-Terrada, and P.E. Zage.  2016.  Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.  Genes & Cancer.  7(1-2): 13-26.  PMID:  27014418.

                     Woodfield, S.E., L. Zhang, K. Scorsone, Y. Liu, and P.E. Zage.  2016.  Binimetinib Inhibits MEK and Is Effective Against Neuroblastoma Tumor Cells With Low NF1 Expression.  BMC Cancer.  16: 172.  PMID:  26925841.

                     Whittle, S., S. Reyes, M. Du, M. Gireud, L. Zhang, S.E. Woodfield, M. Ittmann, M. Scheurer, A.J. Bean, and P.E. Zage.  2016.  A Polymorphism in the FGFR4 Gene is associated with Risk of Neuroblastoma and Altered Receptor Degradation.  Journal of Pediatric Hematology/Oncology. 38(2):  131-8.  PMID:  26840079

                     Zhang, L., K. Scorsone, S.E. Woodfield, and P.E. Zage.  2015.  Sensitivity of Neuroblastoma to the Novel Kinase Inhibitor Cabozantinib Is Mediated by ERK Inhibition.  Cancer Chemotherapy & Pharmacology.  76(5): 977-87.  PMID:  26407819

                     Zhang, L., S. Agarwal, J.M. Shohet, and P.E. Zage.  2015.  CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.  Anticancer Research.  35(7): 3787-92.  PMID: 26124323.

                     Zhang, H., J. Dou, Y. Fan, Y. Yu, J. Cheng, X. Xu, W. Liu, Y. Zhao, S. Guan, Z. Chen, Y. Shi, R. Patel, S.A. Vasudevan, P.E. Zage, H. Zhang, J.G. Nuchtern, E.S. Kim, S. Fu, and J. Yang.  2015.  mTOR ATP-Competitive Inhibitor INK128 Inhibits Neuroblastoma Growth Via Blocking mTORC Signaling.  Apoptosis.  20(1): 50-62.  PMID:  25425103

                     Scorsone, K.S., L. Zhang, S.E. Woodfield, J. Hicks, and P.E. Zage.  2014.  The Novel Kinase Inhibitor EMD1214063 Is Effective Against Neuroblastoma.  Investigational New Drugs.  32: 815-24.  PMID:  24832869

                     Brown, B.S., T. Patanam, K. Mobli, C. Celia, P.E. Zage, A.J. Bean, E. Tasciotti.  2014.  Etoposide-Loaded Immunoliposomes as Active Targeting Agents for GD2 Positive Malignancies.  Cancer Biology & Therapy.  15: 851-61.  PMID:  24755919

                     Stricker, T., A. Morales La Madrid, A. Chlenski, L. Guerrero, H.R. Salwen, Y. Gosiengfiao, E.J. Perlman, W. Furman, A. Bahrami, J.M. Shohet, P.E. Zage, J. Hicks, H. Shimada, R. Suganuma, J.R. Park, S. So, W.B. London, P. Pytel, K.H. Maclean, and S.L. Cohn.  2014.  Validation of a Prognostic Multi-gene Signature in High-risk Neuroblastoma using the High Throughput Digital Nanostring nCounterTM System.  Molecular Oncology.  8: 669-78.  PMID:  24560446

                     Sirisaengtaksin N., M. Gireud, Q. Yan, Y. Kubota, D. Meza, J. Waymire, P.E. Zage, and A.J. Bean.  2014.  UBE4B Couples Ubiquitination and Sorting Machineries to Enable EGFR Degradation.  Journal of Biological Chemistry.  289: 3026-39. PMID: 24344129

                     Zage, P.E.*, N. Sirisaengtaksin*, Y. Liu, M. Gireud, B.S. Brown, S. Palla, K.N. Richards, D.P.M. Hughes, and A.J. Bean.  2013.  UBE4B Levels Are Correlated with Clinical Outcomes in Neuroblastoma Patients and with Altered Neuroblastoma Cell Proliferation and Sensitivity to EGFR Inhibitors.  Cancer.  119:  915-23.  PMID:  22990745

                     Zage, P.E., C.U. Louis, and S.L. Cohn.  2012.  New Aspects of Neuroblastoma Treatment:  ASPHO 2011 Symposium Review.  Pediatric Blood & Cancer.  58: 1099-105.  PMID:  22378620

                     Zage, P.E.*, R. Nolo*, W. Fang, J. Stewart, G. Garcia-Manero, and P.A. Zweidler-McKay.  2012.  Notch Pathway Activation Induces Neuroblastoma Tumor Cell Growth Arrest.  Pediatric Blood & Cancer.  58: 682-9.  PMID:  21744479

                     Levy, A.G.*, P.E. Zage*, L.J. Akers, M.L. Ghisoli, Z. Chen, W. Fang, S. Kannan, T. Graham, L. Zeng, R. Nolo, A.R. Franklin, P. Huang, and P.A. Zweidler-McKay.  2012.  The Combination of the Novel Glycolysis Inhibitor 3-BrOP and Rapamycin is Effective Against Neuroblastoma.  Investigational New Drugs.  30: 191-9.  PMID:  20890785.

                     Zage, P.E. and A.J. Bean.  2012.  Growth Factor Receptor Trafficking as a Potential Therapeutic Target in Pediatric Cancer.   Frontiers in Biology.  7 (1):  1-13.  (Cover Picture)

                     Singh, A., C. Rokes, M. Gireud, S. Fletcher, J. Baumgartner, G. Fuller, J. Stewart, P. Zage, and V. Gopalakrishnan.  2011.  Retinoic Acid Induces REST Degradation and Neuronal Differentiation by Modulating the Expression of SCF-TRCP in Neuroblastoma Cells.  Cancer.  117: 5189-202.  PMID:  21523764.

                     Zage, P.E., T. Graham, L. Zeng, W. Fang, C. Pien, K. Thress, C. Omer, J.L. Brown, and P.A. Zweidler-McKay.  2011.  The Selective Trk Inhibitor AZ623 Inhibits BDNF-Mediated Neuroblastoma Cell Proliferation and Signaling and Is Synergistic with Topotecan.  Cancer.  117: 1321-9.  PMD: 20960503

                     Das, C.M.*, P.E. Zage*, P. Taylor, D. Aguilera, J.E.A. Wolff, D. Lee, V. Gopalakrishnan.  2010.  Chromatin Remodeling at the Topoisomerase-II Promoter is Associated with Enhanced Sensitivity to Etoposide in Human Neuroblastoma Cell Lines.  European Journal of Cancer.  46(15):  2771-80.  PMID:  20886683.

                     Richards, K.N., P.A. Zweidler-McKay, N. Van Roy, F. Speleman, J. Trevino, P.E. Zage, and D.P.M. Hughes.  2010.  Signaling of ERBB Receptor Tyrosine Kinases Promotes Neuroblastoma Growth In Vitro and In Vivo.  Cancer. 116: 3233-43.  PMID:  20564646.

                     Nilsson, M.B, P.E. Zage, L. Zeng, L. Xu, T. Cascone, H.K. Wu, B. Saigal, P.A. Zweidler-McKay, and J.V. Heymach.  2010.  Multiple Receptor Tyrosine Kinases Regulate HIF-1 and HIF-2 in Normoxia and Hypoxia in Neuroblastoma:  Implications for Antiangiogenic Mechanisms of Multikinase Inhibitors.  Oncogene.  29(20): 2938-49.  PMID:  20208561

                     Zage P.E., L. Zeng, S. Palla, W. Fang, M.B. Nilsson, J.V. Heymach, and P.A. Zweidler-McKay.  2010.  A Novel Therapeutic Combination for Neuroblastoma:  the VEGFR/EGFR/RET Inhibitor Vandetanib with 13-cis-Retinoic Acid.  Cancer. 116(10): 2465-75.  PMID:  20225331

                     Thress, K., T. MacIntyre, H. Wang, D. Whitston, Z.-Y. Liu, E. Hoffman, T. Wang, J.L. Brown, K. Webster, C. Omer, P.E. Zage, L. Zeng, and P.A. Zweidler-McKay.  2009.   Identification and Preclinical Characterization of AZ-23, a Novel, Selective, and Orally Bioavailable Inhibitor of the Trk Kinase Pathway.  Molecular Cancer Therapeutics.  8(7):  1818-27.  PMID 19509272

                     Chlenski, A., S. Liu, L.J. Guerrero, Q. Yang, Y. Tian, H.R. Salwen, P. Zage, and S.L. Cohn.  2006.  SPARC Expression is Associated with Impaired Tumor Growth, Inhibited Angiogenesis and Changes in the Extracellular Matrix.  International Journal of Cancer.  118:  310-6.  PMID:  16052522

                     Liu, S., Y. Tian, A. Chlenski, Q. Yang, P.E. Zage, H. Salwen, S. Crawford, and S.L. Cohn.  2005.  "Cross-Talk" Between Schwann Cells and Neuroblasts Influences Tumor Differentiation, Apoptosis, and Angiogenesis.  American Journal of Pathology.  166:  891-900.  PMID:  15743800

                     Yang, Q., P.E. Zage, D. Kagan, Y. Tian, R. Seshadri, H.R. Salwen, S. Liu, A. Chlenski, and S.L. Cohn.  2004.  Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma.  Clinical Cancer Research.  10:  8493-500.  PMID:  15623630